Rising Biosciences (Rising Biosciences) Debt-to-Revenue : 0.00 (As of . 20)

View and export this data going back to . Start your Free Trial

What is Rising Biosciences Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Rising Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was $0.00 Mil. Rising Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was $0.00 Mil. Rising Biosciences's annualized Revenue for the quarter that ended in . 20 was $0.00 Mil.

Rising Biosciences Debt-to-Revenue Historical Data

The historical data trend for Rising Biosciences's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rising Biosciences Debt-to-Revenue Chart

Rising Biosciences Annual Data

Trend

Debt-to-Revenue

Rising Biosciences Quarterly Data

Debt-to-Revenue

Competitive Comparison of Rising Biosciences's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Rising Biosciences's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rising Biosciences's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Rising Biosciences's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Rising Biosciences's Debt-to-Revenue falls into.

Rising Biosciences Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Rising Biosciences's Debt-to-Revenue for the fiscal year that ended in . 20 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(	+	)	/	N/A
	=	N/A

Rising Biosciences's annualized Debt-to-Revenue for the quarter that ended in . 20 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(	+	)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (. 20) Revenue data.

Rising Biosciences Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Rising Biosciences's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Rising Biosciences (Rising Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rising Biosciences Inc (GREY:RBII) » Definitions » Debt-to-Revenue

Traded in Other Exchanges

N/A

Address

1180 Cleveland Road, Sandusky, OH, USA, 44870

Website

http://www.risingbiosciences.com

Rising Biosciences Inc is a United States-based company engaged in research and development activities. It is focused on oral and topical cannabis and non-cannabis based pharmaceuticals. The company seeks to address the market demand for the treatment of the danger of opiates, whose long-term effects can include liver damage, addiction and brain damage due to hypoxia, resulting from respiratory depression, among other complications.